Yes, 3-10 percent of general population, but higher in HIV. It is almost a certainty with over 800 patients in the HIV population that some patients on leronlimab also have NASH. Looking up numbers, I found this old abstract from CRIO, so especially the combo group, I suspect many have NASH.


http://www.croiconference.org/sessions/nash-hiv

Quote:

---

Nonalcoholic fatty liver disease has become the most frequent liver disease in the aging HIV-infected population, with a prevalence at 35%. Its severe form, nonalcoholic steatohepatitis (NASH), is found in 65% of HIV mono-infected patients with chronic elevation of transaminases, which is a frequent occurrence in the practice of HIV medicine. A complex multifactorial pathogenesis, including frequent metabolic comorbidities, lifelong use of antiretroviral therapy and HIV itself, is thought to drive this epidemic. Early diagnosis, preventive and therapeutic strategies may help reduce the burden of NASH in people living with HIV.

---